Antigenics has indicated that GlaxoSmithKline’s (GSK) Phase III malaria vaccine clinical trial, containing Antigenics’ QS-21 Stimulon adjuvant, has enrolled more than 5,000 children to date and is expected
Nabi Biopharmaceuticals has completed the sale of PentaStaph (Pentavalent S. aureus Vaccine) and related assets to GlaxoSmithKline (GSK), which was announced in August 2009. Under the terms of
XOMA seeks to initiate an investigator sponsored phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. The trial
The US Food and Drug Administration (FDA) has granted orphan drug designation to GenVec’s TNFerade, for the treatment of pancreatic cancer. The company said that the FDA grants
The company claims that the SQiDworks Diagnostics Platform and its IgXPLEX RA assay provide clinical laboratories with the ability to simultaneously measure multiple biomarkers in a single test
Ironwood Pharmaceuticals and Forest Laboratories have reported positive top-line results from two phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug
SurModics and NuPathe have entered into a license agreement for drug delivery technology. The companies aim to develop NuPathe’s NP201, the first long-acting treatment available in broadly acceptable
Amylin Pharmaceuticals (Amylin) and Eli Lilly have issued statement in response to the FDA update on Byetta (exenatide) injection. On October 30, the FDA approved an expanded indication
Novartis reported that it will invest $1billion over the next five years, increasing R&D activities in China. The company’s investment will include a significant expansion of The Novartis
Addex has presented results from studies of its lead clinical candidate, ADX10059, in animal models of parkinson’s disease levodopa induced dyskinesia (PD-LID) at the Discovery on Target GPCR-based
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.